Clinical trial
Phase II Open Label Multicenter Study For Age Related Macular Degeneration…
NCT00713518 · Quark Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00713518 |
|---|---|
| Title | Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). |
| Official title | Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study). |
| Acronym | MONET |
| Lead sponsor | Quark Pharmaceuticals, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655 |
| Enrollment | 152 |
| Start date | Nov 1, 2009 |
| Primary completion | Nov 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Jul 11, 2008 |
| Last update posted | Oct 12, 2012 |
| Countries | Austria, Denmark, Hong Kong, India, Israel, Philippines, South Korea, Spain, Taiwan, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: